# Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

> **NCT01343641** · PHASE2 · WITHDRAWN · sponsor: **University of Virginia**

## Conditions studied

- Chronic Kidney Disease
- Kidney Disease

## Interventions

- **DRUG:** MK-0677
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01343641
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Could not obtain drug supply from manufacturer
- **Last updated:** 2018-05-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01343641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01343641, "Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01343641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*